Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Guardian - UK
The Guardian - UK
Business
Nick Fletcher

GlaxoSmithKline sees $2.6bn bid for US partner Human Genome rejected

GlaxoSmithKline has made a $2.6bn bid for US partner Human Genome Sciences, which has been immediately rejected.

The drugs sector has seen a wave of mergers and acquisitions, and Glaxo was said earlier this year to be eyeing up Human Genome, with the two already collaborating on a number of projects including an experimental heart drug.

But the move has been rebuffed by the US company which said the unsolicited offer did not reflect its underlying value. It is now exploring strategic options, and Glaxo has been invited to take part in this process.

Glaxo's shares have added 17p to 1458.5p ahead of a statement from the UK company.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.